0.8789

6.62% -0.0623

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $0.8789, with a volume of 124.77K. It is down -6.62% in the last 24 hours and up +8.61% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Previous Close:

$0.9412

Open:

$0.9411

24h Volume:

124.77K

Relative Volume:

0.50

Market Cap:

$42.45M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.2863

EPS:

-3.07

Net Cash Flow:

$-74.41M

1W Performance:

-8.19%

1M Performance:

+8.61%

6M Performance:

-26.76%

1Y Performance:

-20.10%

1-Day Range:

$0.851

$0.9411

1-Week Range:

$0.81

$1.10

52-Week Range:

$0.49

$1.93

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-09

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO	0.8789	42.45M	0	-81.22M	-74.41M	-3.07
VRTX	447.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	746.00	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.80	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.91	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.73	24.49B	3.30B	-501.07M	1.03B	11.54

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Nov 11, 2024

Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World

Nov 11, 2024

Nov 08, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz

Nov 07, 2024

Xilio Therapeutics Announces Initial Clinical Trial Data - GlobeNewswire

Nov 07, 2024

Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan

Nov 07, 2024

Xilio to present new cancer treatment data at SITC By Investing.com - Investing.com Canada

Nov 07, 2024

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.

Oct 30, 2024

Oct 25, 2024

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St

Oct 25, 2024

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan

Oct 04, 2024

Oct 02, 2024

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com

Oct 02, 2024

Sep 23, 2024

XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com

Sep 23, 2024

XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com

Sep 23, 2024

XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 23, 2024